GM1 Oligosaccharide Efficacy in Parkinson’s Disease: Protection against MPTP

Past evidence has shown that the exogenous administration of GM1 ganglioside slowed neuronal death in preclinical models of Parkinson’s disease, a neurodegenerative disorder characterized by the progressive loss of dopamine-producing neurons: however, the physical and chemical properties of GM1 (i.e...

Descripción completa

Detalles Bibliográficos
Autores principales: Fazzari, Maria, Lunghi, Giulia, Henriques, Alexandre, Callizot, Noëlle, Ciampa, Maria Grazia, Mauri, Laura, Prioni, Simona, Carsana, Emma Veronica, Loberto, Nicoletta, Aureli, Massimo, Mari, Luigi, Sonnino, Sandro, Chiricozzi, Elena, Di Biase, Erika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216367/
https://www.ncbi.nlm.nih.gov/pubmed/37238977
http://dx.doi.org/10.3390/biomedicines11051305

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216367/
https://www.ncbi.nlm.nih.gov/pubmed/37238977
http://dx.doi.org/10.3390/biomedicines11051305

Ejemplares similares